Akademik Veri Yönetim Sistemi
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2024 (SCI-Expanded)
BackgroundThe optimal goal in the management of refractory/relapsed classical Hodgkin lymphoma (R/R-cHL) is to obtain minimal disease status before stem cell transplantation (SCT). The efficiency of BEGEV (bendamustin, gemcitabine, vinorelbine) regimen is well-established as first-line salvage therapy in earlier studies. The search for novel treatment continues for patients with limited options in later lines. This study aimed to evaluate the efficacy of BEGEV regimen in heavily pretreated, platinum-resistant, R/R-cHL.MethodsIn this single-center retrospective trial, patients diagnosed with R/R-cHL between 2018 and 2023 were analyzed. Patients who received BEGEV in third- or fourth-line treatment were eligible. Patient's demographic characteristics, pathology results, treatment and survival outcomes were recorded. Overall survival (OS), objective response rate (ORR), progression free survival (PFS) and toxicity were analyzed.ResultsA total of 31 patients were included in this study. 27 (87.2%) patients were treated with BEGEV in the 3rd line and 4 (12.8%) patients were treated in the 4th line. The results show an ORR of 90.3%, with 54.9% achieving complete response. The median PFS and OS after the BEGEV regimen was 20.2 (range 15-23.6) and 23.2 (range 15.4-40.8) months, respectively. The regimen demonstrated acceptable toxicity, with the most common severe adverse events being neutropenia and thrombocytopenia. SCT was successfully performed in 100% of the patients after BEGEV treatment.ConclusionOur findings suggest that BEGEV is a viable and effective treatment option for heavily pretreated, platinum-resistant R/R-cHL patients, particularly in regions with limited access to novel therapies.